Overview
Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.